A statement released earlier today by Vetr Inc. about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) bumps the target price to $93.98
- Updated: November 29, 2016
Stating a potential upside of 0.07%, Vetr Inc. upped the price target of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $93.98
On 11/28/2016, Vetr Inc. released a statement on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) upped the target price from $0.00 to $91.77 that suggested an upside of 0.03%.
Having a price of $88.10, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded -1.88% lower on the day. With the last close down -3.30% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. BioMarin Pharmaceutical Inc. has recorded a 50-day average of $86.14 and a two hundred day average of $89.66. Volume of trade was down over the average, with 0 shares of BMRN changing hands under the typical 1,238,120
With a total market value of $0, BioMarin Pharmaceutical Inc. has with a one year low of $62.12 and a one year high of $107.56 .
A total of 20 analysts have released a report on BioMarin Pharmaceutical Inc.. Six analysts rating the company a strong buy, eleven analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $116.10.
More About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.